Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Cancer nanomedicine: is targeting our target?

Nature Reviews Materials volume 1, Article number: 16069 (2016) Cite this article

Subjects

An Erratum to this article was published on 09 September 2016

Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Torrice, M. Does nanomedicine have a delivery problem? ACS Cent. Sci. 2, 434–437 (2016).

    Article  CAS  Google Scholar 

  2. Venditto, V.J. & Szoka, F.C. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80–88 (2013).

    Article  CAS  Google Scholar 

  3. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    Article  CAS  Google Scholar 

  4. Lammers, T., Rizzo, L.Y., Storm, G. & Kiessling, F. Personalized nanomedicine. Clin. Cancer Res. 18, 4889–4894 (2012).

    Article  CAS  Google Scholar 

  5. Tietjen, G.T. & Saltzman, W.M. Nanomedicine gets personal. Sci. Transl. Med. 7, 314fs47 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

T.L. gratefully acknowledges support by the European Research Council (StG-309495, PoC-680882) and by the German Research Foundation (LA 2937/1-2).

Author information

Authors and Affiliations

  1. Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, 52074, Germany

    Twan Lammers & Fabian Kiessling

  2. Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 7500, AE, The Netherlands

    Twan Lammers & Gert Storm

  3. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584, CG, The Netherlands

    Twan Lammers, Wim Hennink, Daan Crommelin & Gert Storm

  4. Pharmaceutical Science, Innovative Medicines, AstraZeneca, Macclesfield, SK10 2NA, UK

    Marianne Ashford

Authors
  1. Twan Lammers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabian Kiessling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianne Ashford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wim Hennink
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daan Crommelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gert Storm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Twan Lammers or Daan Crommelin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lammers, T., Kiessling, F., Ashford, M. et al. Cancer nanomedicine: is targeting our target?. Nat Rev Mater 1, 16069 (2016). https://doi.org/10.1038/natrevmats.2016.69

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/natrevmats.2016.69

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer